Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor

Bibliography

• Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev 2006;6:38-51
   Google Scholar
• Plumb JA, Finn PW, Williams RJ, et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2003;2:721-8
   PubMed Web of Science ®Google Scholar
• Finn PW, Bandara M, Butcher C, et al. Novel sulfonamide derivatives as inhibitors of histone deacetylase. Helvetica Chimica Acta 2005;88:1630-57
   Web of Science ®Google Scholar
• Khan N, Jeffers M, Kumar S, et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008;409:581-9
   PubMed Web of Science ®Google Scholar
• Grozinger CM, Schrieber SL. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem Biol 2002;9:3-16
   PubMed Web of Science ®Google Scholar
• Chiba T, Yokosuka O, Fukai K, et al. Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor trichostatin A on human hepatoma cells. Oncology 2004;66:481-91
   PubMed Web of Science ®Google Scholar
• Glaser KB, Staver MJ, Waring JF, et al. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2003;2:151-63
   PubMed Web of Science ®Google Scholar
• Lee H, Lee S, Baek M, et al. Expression profile analysis of trichostatin A in human gastric cells. Biotech Lett 2002;24:377-81
   Web of Science ®Google Scholar
• Tumber A, Collins LS, Petersen KD, et al. The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemother Pharmacol 2007;60:275-83
   PubMed Web of Science ®Google Scholar
• Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8
   PubMed Web of Science ®Google Scholar
• Qian X, LaRochelle WJ, Ara G, et al. Activity of the HDAC inhibitor, PXD101, used as monotherapy and combination therapy in preclinical NSCLC studies [abstract 4743]. In: Proceedings of the 97th Annual Meeting of the American Association for Cancer Research, 1–5 April 2006, Washington, DC, USA. Philadelphia. p. 1114
   Google Scholar
• Jones RB, Gordus A, Krall JA, MacBeath G. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 2006;439:168-74
   PubMed Web of Science ®Google Scholar
• Sehested M. Personal communication (1 November 2008), data on file at TopoTarget
   Google Scholar
• Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008;8:579-91
   PubMed Web of Science ®Google Scholar
• Shoemaker R, Hose C, Pezzoli P, et al. Defining a set of genes dysregulated in response to the HDAC inhibitor PXD101 (belinostat) [abstract A129]. In: Proceedings of the 98th Annual Meeting of the American Association for Cancer Research; AACR Meeting Abstracts, Oct 2007
   Google Scholar
• Lampson MA, Renduchitala K, Khodjakov A, Kapoor TM. Correcting improper chromosome-spindle attachments during cell division. Nat Cell Biol 2004;6:232-7
   PubMed Web of Science ®Google Scholar
• Bischoff JR, Plowman GD. The Aurora lpl 1p kinase family: regulators of chromosome segregation and cytokinesis. Trends Cell Biol 1999;9:454-9
   PubMed Web of Science ®Google Scholar
• Kaufmann WK, Paules RS. DNA damage and cell cycle checkpoints. FASEB J 1996;10:238-47
   PubMed Web of Science ®Google Scholar
• Beck HC, Nielsen EC, Rune Matthiesen R, et al. Quantitative proteomic analysis of posttranslational modifications of human histones. Mol Cell Proteomic 2006;5:1314-25
   PubMed Web of Science ®Google Scholar
• NCI screening (NSC 726630). Available from: http//dtp.nci.nih.gov [last accessed 15 December 2008]
   Google Scholar
• Qian X, LaRochelle WJ, Ara G, et al. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther 2006;5:2086-95
   PubMed Web of Science ®Google Scholar
• Qian X, Ara G, Mills E, et al. Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer. Int J Cancer 2008;122:1400-10
   PubMed Web of Science ®Google Scholar
• Buckley MT, Yoon J, Yee H, et al. The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo. J Transl Med 2007;5:49
   PubMed Web of Science ®Google Scholar
• Campbell RA, Sanchez E, Chen H, et al. Effects of a novel histone deacetylase inhibitor, PXD101, when used as monotherapy or in combination with bortezomib on tumor growth in mouse models of human multiple myeloma [abstract 3483]. ASH Annual Meeting Abstracts. Blood 2006;108:3483
   Web of Science ®Google Scholar
• Kim MS, Blake M, Baek JH, et al. Inhibition of histone deacetylase increases cytotoxicity to anti-cancer drugs targeting DNA. Cancer Res 2003;63:7291-300
   PubMed Web of Science ®Google Scholar
• Jang ER, Lim S, Lee ES, et al. The histone deacetylase inhibitor trichostatin A sensitises estrogen receptor α-negative breast cancer cells to tamoxifen. Oncogene 2003;23:1-13
   Web of Science ®Google Scholar
• Marchion DC, Bicaku E, Daud AI, et al. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hyroxamic acid. J Cell Biochem 2004;92:223-37
   PubMed Web of Science ®Google Scholar
• Ritchie JWA, Tumber AM, Edwards NJ, et al. The novel histone deacetylase inhibitor PXD101 synergises with established chemotherapeutics to inhibit tumour cell proliferation and upregulate apoptosis in vitro. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, 17–21November 2003, Boston, MA, USA [abstract A150]. Clin Cancer Res 2003;9:6069
   Google Scholar
• Hubbert C, Guardiola A, Shao R, et al. HDAC6 is a microtubule-associated deacetylase. Nature 2002;417:455-8
   PubMed Web of Science ®Google Scholar
• Diamanti P, Cox CV, Blair A, et al. Investigation of the efficacy of PXD101 (belinostat) on primary leukaemic cells and cell lines as a novel agent for childhood acute lymphoblastic leukaemia (ALL) [abstract 2793]. ASH Annual Meeting Abstracts. Blood 2007;110:2793
   PubMed Web of Science ®Google Scholar
• Feng R, Oton A, Mapara MY, et al. The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage. Br J Haematol 2007;139:385-97
   PubMed Web of Science ®Google Scholar
• Lentzsch S, Anderson G, Cuiling LI, et al. Combination of proteasome inhibitor PS 341 (Velcade®) with histone acetylase inhibitor (HDAC) PXD 101 shows superior anti-myeloma activity and inhibits osteoclastogenesis [abstract 2488]. ASH Annual Meeting Abstracts Blood 2005;106:2488
   Google Scholar
• Dai Y, Chen S, Kramer L, et al. The HDAC inhibitors romidepsin and PXD101 interact synergistically with Bortezomib in human chronic lymphocytic leukemia (CLL) cells in association with NF-B inactivation. AACR Meeting Abstracts 2007;1835
   Google Scholar
• Warren KE, McCully C, Dvinge H, et al. Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates. Cancer Chemother Pharmacol 2008;62:433-7
   PubMed Web of Science ®Google Scholar
• Steele NL, Plumb JA, Vidal L, et al. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 2008;14:804-10
   PubMed Web of Science ®Google Scholar
• Gimsing P, Hansen M, Knudsen LM, et al. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced haematological neoplasias. Eur J Haematol 2008;81:170-6
   PubMed Web of Science ®Google Scholar
• Kelly W, Petrylak D, Blumenschein G, et al. A phase I study of oral administration of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors [abstract 404]. 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Eur J Cancer Suppl 2008;6:127
   Web of Science ®Google Scholar
• Sullivan D, Singhal S, Schuster M, et al. A phase II study of PXD101 in advanced multiple myeloma. ASH (Annual Meeting Abstracts) Nov 2006;108:3583
   Google Scholar
• Schlenk R, Sohlbach K, Hütter ML, et al. Interim results of a phase I/II clinical trial of belinostat in combination with idarubicin in patients with AML not suitable for standard intensive therapy. ASH (Annual Meeting Abstracts) Nov 2008;112:1953
   Google Scholar
• Odenike O, Green M, Larson RA, et al. Phase I study of Belinostat (PXD101) plus azacitidine (AZC) in patients with advanced myeloid neoplasms [abstract 7057]. American Society of Clinical Oncology (ASCO) Meeting Abstracts 2008 J Clin Oncol 2008;26(May 20 Suppl.)
   Google Scholar
• Foss F, Pohlman B, Jacobsen E, et al. Phase II open-label trial of belinostat in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma. [abstract 241] 10th International Conference on Malignant Lymphoma, 2008, Lugano, Switzerland. Ann Oncol 2008;19(Suppl 4)
   Google Scholar
• Yeo W, Lim R, Ma BB, et al. A phase I/II study of belinostat (PXD101) in patients with unresectable hepatocellular carcinoma [abstract 15081]. American Society of Clinical Oncology (ASCO) Meeting Abstracts 2007 J Clin Oncol 2007;25(June 20 Suppl.)
   Google Scholar
• Mackay HJ, Hirte H, Covens A, et al. A phase II trial of the histone deacetylase inhibitor belinostat ( PXD101) in patients with platinum resistant epithelial ovarian tumors and micropapillary/borderline (LMP) ovarian tumors [abstract 5518]. A trial of the PMH Phase II Consortium. American Society of Clinical Oncology (ASCO) Meeting Abstracts 2008 J Clin Oncol 2008;26(May 20 Suppl.)
   Google Scholar
• Lassen U, Braly PS, de Bono J, et al. Phase I/II study of the histone deacetylase inhibitor belinostat in combination with carboplatin and paclitaxel in advanced solid tumors (phI) and relapsed ovarian cancer (ph II)) [abstract 560]. ESMO Annual Meeting, 2008, Stockholm, Sweden. Ann Oncol 2008;11(Suppl 8)
   Google Scholar
• Sørensen M, Tjørnelund J, Jensen PB, Lassen U. A phase I safety and pharmacokinetic (PK) study of 3 and 6 hours (h) intravenously administered belinostat (PXD101)plus carboplatin (C) and paclitaxel (P) in patients (pts) with advanced solid tumours [poster 419]. 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, October 2008. Eur J Cancer Suppl 2008;6:132
   Web of Science ®Google Scholar
• Finkler NJ, Dizon DS, Braly P, et al. Phase II multicenter trial of the histone deactylase inhibitor (HDACi) belinostat, carboplatin and paclitaxel (BelCaP) in patients (pts) with relapsed epithelial ovarian cancer (EOC) [abstract 5519]. American Society of Clinical Oncology (ASCO) Meeting Abstracts 2008 J Clin Oncol 2008;26(May 20 Suppl.)
   Google Scholar
• Barriuso J, Daugaard G, Frentzas S, et al. Phase II multicenter trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) for patients (pts) with transitional cell carcinoma (TCC) of the bladder [poster 213]. 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, October 2008. Eur J Cancer 2008;6(Suppl):67-8
   Web of Science ®Google Scholar
• Brunetto A, Krarup-Hansen A, Nielsen OS, et al. A Phase I clinical trial of belinostat (PXD101) in combination with doxorubicin (BelDox) in advanced solid tumours, including soft tissue sarcomas (STS) [poster 420]. 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, October 2008. Eur J Cancer Suppl 2008;6:132
   Web of Science ®Google Scholar
• Northfelt DW, Bonnem E, Fagerberg J, et al. Belinostat down-regulates thymidylate synthase in tumor tissue: a dose-escalation study of belinostat alone and in combination with 5-fluorouracil (FU) [abstract 333]. 2009 Gastrointestinal Cancers Symposium, 15 – 17 January 2009, San Francisco, California, USA
   Google Scholar
• O'Bryant CL, Leong S, Camidge DR, et al. A Phase 1 study of belinostat (PXD101) in combination with bortezomib in patients with advanced solid tumors and lymphoma [abstract A149]. 19th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, October 2007. Eur J Cancer Suppl 2007;5
   Google Scholar